Effect of Acute Sleep Restriction on Responses to Hypoxia

NCT ID: NCT05563688

Last Updated: 2022-11-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

25 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-10-26

Study Completion Date

2024-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

At altitude, humans are exposed to environmental hypoxia induced by the decrease in barometric pressure. On duty or in training, mountain troops, paratroopers or aircrew are regularly exposed to altitude. The effects of altitude on humans occur gradually from 1500 m and depend on both the duration of exposure and the altitude level. Cognitive disorders can occur from 3500 m (threshold of disorders) but there is a very large inter-individual variability.

The countermeasure to altitude hypoxia is oxygen but its use is not systematic between 3000 and 4000 m. Its use depends on the duration of exposure, without clearly established standards. Incapacitating effects on the operational capacity and health of soldiers can therefore occur as early as 3500 m.

In operations or during training, altitude exposure is often associated with a significant sleep debt (particularly during night or early morning missions), jet lag or precarious rest conditions in overseas operations. These sleep restrictions promote the degradation of mental performance with effects similar to those observed in hypoxia.

The combination of these constraints induces a physiological stress which can favour alterations in mental performance, an increase in incapacity, intolerance to altitude or the occurrence of altitude-related pathologies in military personnel. This could occur in particular in the operational zone around the threshold of disorders (3500 m) where the indication of oxygen is discussed.

The objective of this study is to assess the impact of acute sleep restriction on hypoxia tolerance.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sleep Deprivation Hypoxia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CROSSOVER

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hypoxia exposure

Each participant will be exposed to the hypoxic environment on 2 occasions (one after a normal sleep night and one after sleep deprivation).

Each exposure will be for 5 hours at a FiO2 of 13.2% (3500 m simulated altitude).

This exposure will be carried out in a normobaric hypoxic tent (Sporting Edge®).

Intervention Type OTHER

Sleep deprivation

Each participant will be exposed to sleep deprivation on 2 occasions (one before normoxia exposure and one before hypoxia exposure).

Each sleep deprivation involves a time spent in bed of 3 hours (03h00 - 06h00). Sleep deprivation will be carried out in a sleep apartment. Sleep duration and quality will be assessed using a sleep headband (Dreem®), actigraphs Actiwatch® and E4 Empatica®) and a sleep diary.

Intervention Type OTHER

Cognitive tasks

Participants will perform several cognitive tasks in the following conditions:

* in normoxia (FiO2 = 21%) after a night of usual sleep (\> 6 hours) ;
* in normoxia (FiO2 = 21%) after a night of reduced sleep (3 hours);
* in normobaric hypoxia (FiO2 = 13.2%) after a night of normal sleep (\> 6 hours);
* in normobaric hypoxia (FiO2 = 13.2%) after a night of reduced sleep (3 hours).

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male
* Healthy
* Between 18 and 45
* Smoking \< 5 cigarettes per day or nicotine-free electronic cigarette
* Having regular physical activity (between 1 and 4 hours of physical activity per week)
* Affiliated or entitled to a social security plan
* No contraindication to physical exercise
* Having given their consent

Exclusion Criteria

* Female
* BMI \> 30
* Active medical pathology (cardiological, renal, hepatic, cutaneous, neurological, etc.),
* History of active pathology of less than 6 months
* Significant deviation with the normal values observed during the interrogation, clinical examination or electrocardiogram
* Having spent time at altitude (\> 3500 m) during the last 3 months
* Absolute or relative contraindication to a stay at high altitude
* Medical contraindication to sport practice
* Skin allergy to modified ethanol or capsaicin
* Wearing a pacemaker or ferromagnetic implants
* Poor venous capital
* Pittsburgh Sleep Quality Index Questionnaire \> 5
* Usual sleep duration \< 6 hours
* Not covered by a health insurance plan
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Direction Centrale du Service de Santé des Armées

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Institut de Recherche Biomédicale des Armées

Brétigny-sur-Orge, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Pierre FABRIES, MD

Role: CONTACT

178652089 ext. +33

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Pierre FABRIES, MD

Role: primary

178652089 ext. +33

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022-A00464-39

Identifier Type: OTHER

Identifier Source: secondary_id

2021PBMD09

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Sleep Disturbance in Deployed Soldiers
NCT00860756 UNKNOWN EARLY_PHASE1
Sleep Deprivation Study
NCT05560620 COMPLETED NA